Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Medullary thyroid carcinoma.

Ana O Hoff1, Paulo M Hoff

  • 1Centro de Oncologia, Hospital Sírio Libanês, Sao Paulo, Brazil. hoffao@yahoo.com

Hematology/Oncology Clinics of North America
|June 6, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neoadjuvant pembrolizumab plus chemotherapy in germline BRCA-mutated early triple-negative breast cancer: a multicenter real-world cohort.

NPJ breast cancer·2026
Same author

Medullary thyroid carcinoma and RET molecular testing: A virtual tumor board on clinical decision-making.

CA: a cancer journal for clinicians·2026
Same author

Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer after prior vascular endothelial growth factor receptor-targeted therapy (COSMIC-311): outcomes by BRAF status.

Frontiers in oncology·2026
Same author

Treatment patterns and safety of adjuvant therapy after chemoimmunotherapy for early-stage triple-negative breast cancer: real-world data from the Neo-Real/GBECAM 0123 study.

Breast cancer research and treatment·2026
Same author

Neoadjuvant pembrolizumab plus chemotherapy in older patients with early-stage triple-negative breast cancer: real-world insights from neo-real/GBECAM-0123.

NPJ breast cancer·2026
Same author

A novel less-invasive therapy for a bleeding eroded artery in a giant duodenal ulcer: principles and technical description.

iGIE : innovation, investigation and insights·2026
Same journal

Palliative Therapy for Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Ablative Therapies for Liver Tumors.

Hematology/oncology clinics of North America·2026
Same journal

Pathology of Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Minimally Invasive Surgery for Liver and Biliary Tract Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Surgical Considerations for Primary Liver Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Systemic Therapy for Biliary and Liver Neoplasms: Chemotherapy and Immunotherapy.

Hematology/oncology clinics of North America·2026
See all related articles

Medullary thyroid carcinoma, a rare thyroid cancer, originates from C cells. Early diagnosis in families with multiple endocrine neoplasia type 2 is crucial for effective management.

Area of Science:

  • Endocrinology
  • Oncology
  • Genetics

Background:

  • Medullary thyroid carcinoma (MTC) is a neuroendocrine tumor originating from thyroid C cells, comprising about 5% of thyroid cancers.
  • Around 30% of MTC cases are linked to multiple endocrine neoplasia type 2 (MEN2), an autosomal dominant syndrome.
  • Identifying individuals with MEN2 is vital for early diagnosis and intervention in affected families.

Purpose of the Study:

  • To summarize the key aspects of medullary thyroid carcinoma, including its origin, genetic associations, and current treatment limitations.
  • To highlight the importance of early diagnosis in hereditary MTC cases.
  • To discuss the emerging role of molecular targeted agents in future MTC treatment.

Main Methods:

  • Review of existing literature on medullary thyroid carcinoma.

Related Experiment Videos

  • Analysis of epidemiological data regarding MTC prevalence and associations.
  • Discussion of current therapeutic strategies and emerging molecular targets.

    • Main Results:

    • Medullary thyroid carcinoma is a distinct entity with specific C-cell origin.
    • Hereditary forms, particularly MEN2, necessitate genetic screening and early detection.
    • Current treatments like surgery are primary, with limited efficacy of radiotherapy and chemotherapy.
    • Molecular insights are paving the way for novel targeted therapies.

    Conclusions:

    • Medullary thyroid carcinoma requires specialized management, with a strong emphasis on genetic counseling and early diagnosis for hereditary cases.
    • The limited efficacy of conventional therapies underscores the need for advanced treatment modalities.
    • Ongoing research into molecular pathways promises to revolutionize medullary thyroid carcinoma treatment with targeted agents.